Columbia Care Reports Third Quarter 2019 Financial Results Including 123% Revenue Growth on a Year-over-Year Basis


Ryan Allway

November 6th, 2019

News


Third quarter 2019 revenue of $22.1 million, an increase of 123% over prior year period

Continued organic growth in key markets with 26 dispensaries now operational across 12 jurisdictions, including recent openings in Delaware, Florida and Maryland

The Company has entered into its first M&A transaction with the signing of a definitive agreement to acquire The Green Solution, Colorado’s largest vertically integrated cannabis company

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO:CCHW) (OTCQX:CCHWF) (FSE:3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, today reported financial and operating results for its third quarter ended September 30, 2019. All financial information is provided in US dollars unless otherwise indicated.

Third Quarter 2019 Financial Highlights

  • Revenue of $22.1 million, an increase of 123% from the prior year period, and a sequential increase of 25% for retail sales and 15% in aggregate over the second quarter of 2019
  • Adjusted EBITDA of ($11.3) million compared to ($4.2) million for the prior year period, reflecting on-going execution against the Company’s 2019 growth initiatives, including new and existing market expansion, post-construction/pre-approval facility operating expenses, organizational growth and professional fees
  • Net loss of $19.9 million compared to $5.3 million for the prior year period, reflecting an increase in non-cash expenses as well as the Company’s investment in its growth initiatives and the funding of new markets being brought on-line
  • Completed and staffed 11 additional dispensaries; requested and awaiting final regulatory approval to operate
  • Completed its consolidation of minority interests in the Company’s Illinois operations
  • $84.5 million cash on hand as of September 30, 2019, and no debt

Subsequent to the end of the Third Quarter 2019, the Company:

  • Announced that it has entered into a definitive agreement to acquire The Green Solution through a stock and note transaction initially valued at $140 million.
  • Launched operations in Maryland while expanding its dispensary footprint in Delaware and Florida. Columbia Care is now operational in 12 of its 15 licensed jurisdictions with additional expansion activities on-going.
  • Received approval to operate all 11 dispensaries (including Delaware, Florida, Puerto Rico and Maryland) that were awaiting final approval at the end of Q3
  • Entered into an exclusive agreement with Moeller Pharma GmbH for the development of proprietary, plant-based combination cannabinoid functional health and wellness products
  • Entered into voluntary lockup extensions with company founders, board members and its leadership team covering approximately 60% of those shares subject to the Company’s original lockup agreement

We are delighted to report such strong financial and operational performance for the quarter. Despite continued regulatory challenges, we have maintained our focus on driving towards profitability in existing markets, opening new markets, and innovating to ensure we have better and differentiated products and services. In addition, Columbia Care continues to deliver on its key initiatives, and with today’s announcement of our first acquisition, The Green Solution, we enter a new phase of the Company’s growth cycle, using disciplined M&A as a complement to our core strategy. The combination of these approaches will enable us to maintain our dominant position in the US and global cannabis marketplace,” said Nicholas Vita, chief executive officer of Columbia Care. “Our fundamentals continue to be strong with $22.1M revenue reported in the third quarter, a 123% increase from the prior year, and with almost $85M in cash and no debt on our balance sheet at quarter end, Columbia Care stands apart in its ability to fund existing growth initiatives while having access to multiple financing options for opportunistic activities. By maintaining financial discipline and focusing on our operational execution, we expect our efforts to translate into strong results for the remainder of 2019 and beyond.”

Discussion of Third Quarter 2019 and First Nine Months 2019 Results

Revenue for the third quarter of 2019 totaled $22.1 million, an increase of 123% compared to the third quarter of 2018. Revenue for the nine-month period ended September 30, 2019 was $54.3 million, an increase of 92% compared the prior year period.

Revenue increased due to the Company’s organic growth in its licensed jurisdictions coupled with higher consumer demand for Columbia Care’s medical and wellness cannabis products.

Excluding the impact of fair value adjustments for biological assets, gross profit for the third quarter of 2019 was $5.3 million, an increase of 42% compared to the third quarter of 2018. For the nine-month period ended September 30, 2019, gross profit, excluding the impact of fair value adjustments for biological assets, was $15.1 million, an increase of 21% compared to the prior year period.

The Company’s gross profit for the third quarter of 2019 was $15.7 million, an increase of 39% compared to the third quarter of 2018. For the nine-month period ended September 30, 2019, gross profit was $18.7 million, an increase of 6% compared to the prior year period.

Net loss for the third quarter of 2019 was $19.9 million, compared to $5.3 million for the prior year period, primarily due to higher operating expenses related to equity-based compensation expense, salary and benefit expenses and professional fees. Net loss for the nine-month period ended September 30, 2019 was $78.7 million, compared to $19.2 million for the prior year period, primarily due to equity-based compensation expense, professional fees, listing fee expense and salary and benefit expense.

Adjusted EBITDA for the third quarter of 2019 was ($11.3) million, compared to ($4.2) million for the prior year period. Adjusted EBITDA for the nine-month period ended September 30, 2019 was ($33.0) million, compared to ($8.2) million for the prior year period. Changes in Adjusted EBITDA were primarily driven by higher operating expenses. See “Non-IFRS Financial Measures.”

As of September 30, 2019, the Company had $84.5 million cash on hand and carried no debt.

Conference Call and Webcast Details
The Company will report complete financial results for the third quarter 2019 on Tuesday, November 5, 2019 at 4:30 p.m. EST. To access the live conference call via telephone, please dial 1-877-407-8914 (U.S. callers) or 1-201-493-6795 (international callers), no passcode is required. A live audio webcast of the call will also be available in the Investor Relations section of the Company’s website at https://ir.col-care.com/.

A replay of the audio webcast will be available in the Investor Relations section of the Company’s website approximately 2 hours after completion of the call and will be archived for 30 days.

Non-IFRS Financial Measures
In this press release, Columbia Care refers to certain non-IFRS financial measures, such as Adjusted EBITDA and gross profit excluding changes in fair value of biological assets. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Columbia Care considers certain non-IFRS measures to be meaningful indicators of the performance of its business. A reconciliation of such non-IFRS financial measures to their nearest comparable IFRS measure is included in this press release.

About Columbia Care Inc.
Columbia Care Inc. is one of the largest and most experienced multi-state operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU. With over 1.4 million in sales transactions since its inception, Columbia Care is a patient-centered organization setting the standard for compassion, professionalism, quality, caring and innovation, working in collaboration with some of the most renowned and innovative teaching hospitals and medical centers in the world. The Company is committed to providing the type of education and transparency patients deserve and quality of product that clinicians expect. For more information on Columbia Care, please visit www.col-care.com.

Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Statements concerning Columbia Care’s objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of Columbia Care are forward-looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking information involves numerous assumptions, including the ability of the Company to obtain certain third party consents, permits and approvals; the ability of Columbia Care to meet its dispensary targets, including the ability to negotiate additional lease arrangements satisfactory to the Company; the ability of the Company to complete all planned construction in a timely manner; and the ability of the Company to identify and attract qualified staff. Projections may be impacted by macroeconomic factors, in addition to other factors not controllable by the Company. Columbia Care has also made certain general industry assumptions in the preparation of such forward-looking statements. Management believes that the expectations reflected in forward-looking statements are based upon reasonable assumptions; however, Management can give no assurance that actual results will be consistent with these forward-looking statements. Not all factors which affect the forward-looking information are known, and actual results may vary from the projected results in a material respect and may be above or below the forward-looking information presented in a material respect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Columbia Care’s actual results, performance or achievements, or developments in its industry, to differ materially from the anticipated results, performance, achievements or developments expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Columbia Care’s final prospectus dated March 21, 2019 (the “Prospectus”) and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the Prospectus could cause actual events or results to differ materially from those described in any forward-looking information. Forward-looking statements are based on management’s current plans, estimates, projections, beliefs and opinions, and Columbia Care does not undertake any obligation to update forward-looking statements should assumptions related to these plans, estimates, projections, beliefs and opinions change except as required by applicable securities laws. All of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Columbia Care.

TABLE 1 – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in US $ thousands, except share and per share figures, unaudited)
Three Months Ended Nine Months Ended
September 30, 2019 September 29, 2018 September 30, 2019 September 29, 2018
Revenue

 $

                             22,120

 $

                               9,925

 $

                             54,287

 $

                             28,345

Production costs

                              (16,830

)

(6,189

)

                              (39,167

)

                              (15,821

)

Gross profit before fair value adjustments

5,290

3,736

15,120

12,524

Fair value adjustments biological assets, net

10,389

7,575

3,590

5,194

Gross profit

15,679

11,311

18,710

17,718

Operating expenses

(33,819

)

(15,056

)

                              (95,013

)

                              (32,233

)

Operating loss

                              (18,140

)

(3,745

)

                              (76,303

)

                              (14,515

)

Other expense, net

    (458

)

(1,664

)

    (176

)

(3,585

)

Income tax (expense) benefit

(1,264

)

        95

(2,233

)

(1,141

)

Net loss

                              (19,862

)

(5,314

)

                              (78,712

)

                              (19,241

)

Net loss attributable to non-controlling interests

(1,599

)

   (368

)

(1,947

)

    (835

)

Net loss attributable to Columbia Care shareholders

 $

                          (18,263

)

 $

                            (4,946

)

 $

                          (76,765

)

 $

                          (18,406

)

Weighted average common shares outstanding – basic and diluted

                     216,269,530

                     163,352,801

                     207,729,060

161,564,898

Earnings per common share attributable to Columbia Care shareholders – basic and diluted

 $

                               (0.08

)

 $

                               (0.03

)

 $

                               (0.37

)

 $

                               (0.11

)

TABLE 2 – RECONCILIATION OF IFRS TO NON-IFRS MEASURES
(in US $ thousands, unaudited)
Three Months Ended Nine Months Ended
September 30, 2019 September 29, 2018 September 30, 2019 September 29, 2018
Net loss

 $

                          (19,862

)

 $

                            (5,314

)

 $

                          (78,712

)

 $

                          (19,241

)

Income tax expense (benefit)

  1,264

      (95

)

  2,233

  1,141

Depreciation and amortization

  4,231

  1,238

10,260

  3,386

Net interest and debt amortization

      350

  1,662

  1,175

  3,227

EBITDA

 $

                          (14,017

)

 $

                            (2,509

)

 $

                          (65,044

)

 $

                          (11,487

)

Share-based compensation

13,150

  5,910

24,539

  8,518

Fair value adjustments biological assets, net

                              (10,389

)

(7,575

)

(3,590

)

(5,194

)

Listing fee expense

         –

         –

11,071

         –

Adjusted EBITDA

 $

                          (11,256

)

 $

                            (4,174

)

 $

                          (33,024

)

 $

                             (8,163

)

TABLE 3 – CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(in US $ thousands, unaudited)
Three Months Ended Nine Months Ended
September 30, 2019 September 29, 2018 September 30, 2019 September 29, 2018
Net cash used in operating activities

 $

                          (11,332

)

 $

                            (2,892

)

 $

                          (53,626

)

 $

                          (17,007

)

Net cash used in investment activities

                              (26,714

)

(1,361

)

                              (58,119

)

(7,294

)

Net cash (used in) provided by financing activities

(2,758

)

12,561

                              150,010

33,917

Net (decrease) increase in cash

                              (40,804

)

  8,308

38,265

  9,616

Cash balance – beginning of period

                              125,310

14,605

46,241

13,297

Cash balance – end of period

84,506

22,913

84,506

22,913

TABLE 4 – CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (SELECT ITEMS)
(in US $ thousands, unaudited)
September 30, 2019 December 29, 2018
Cash

 $

                             84,506

 $

                            46,241

Total current assets

                              172,286

                             160,122

Property and equipment, net

95,274

39,794

Right of use assets

42,156

         –

Total assets

                              356,974

                             233,927

Total current liabilities

29,129

15,309

Total liabilities

71,382

30,238

Total equity

                              285,592

                             203,689

Contacts

Investors:
Gary F. Santo, Jr.
Investor Relations
+1.212.271.0915
[email protected]

Media:
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading